Date: 2011-02-03
Type of information: Grant
Company: Digna Biotech (Spain), Centro de Investigación Médica Aplicada (CIMA) de la Universidad de Navarra (Spain)
Investors: European Union
Amount: € 1.3 million
Funding type: grant
Planned used: As part of the AIPGENE grant, Digna Biotech and CIMA will complete a Phase I/II study in humans. With the support of all AIPGENE partners, Digna Biotech anticipates AIP patient enrolment in the trial in early 2012.
Others: Digna Biotech and the Centro de Investigación Médica Aplicada (CIMA) de la Universidad de Navarra announced that the European Union has finalized a € 3.3 million grant to AIPGENE consortium. Digna Biotech and CIMA will receive, as members of the consortium, € 0.5 and 0.8 million respectively for the clinical development of a gene therapy product for Acute Intermittent Porphyria (AIP). The AIPGENE consortium is led by CIMA (University of Navarra), and in addition to Digna Biotech includes Clínica Universidad de Navarra, Amsterdam Molecular Therapeutics (AMT), Stockholms Läns Landsting, Deutsches Krebsforschungszentrum and Servicio Madrileño de Salud. As part of the AIPGENE grant, Digna Biotech and CIMA will complete a Phase I/II study in humans. With the support of all AIPGENE partners, Digna Biotech anticipates AIP patient enrolment in the trial in early 2012. Under a co-development agreement, Digna Biotech transferred to AMT global rights to develop and commercialize this adeno-associated based gene therapy vector for acute intermittent porphyria. AMT was granted Orphan Drug Designation for this vector.
Therapeutic area: Rare diseases
